Bioequivalence Margins Do Not Need Revision For All Generics, Panel Says
Executive Summary
While narrower bioequivalence margins might be necessary for certain categories of generic drugs, FDA's Pharmaceutical Science and Clinical Pharmacology Advisory Committee has determined that the specifications should not be tightened across the board for all generic drug approvals
You may also be interested in...
ANDAs For Narrow Therapeutic Index Drugs May Need Crossover Studies
FDA’s challenges in creating a more specific definition of narrow therapeutic index drugs were on clear display at the most recent advisory committee meeting on the topic: There’s wide support for the project, but equally broad concern that it needs to be more carefully tailored.
ANDAs For Narrow Therapeutic Index Drugs May Need Crossover Studies
FDA’s challenges in creating a more specific definition of narrow therapeutic index drugs were on clear display at the most recent advisory committee meeting on the topic: There’s wide support for the project, but equally broad concern that it needs to be more carefully tailored.
Changes To Generic Drug Bioequivalence Requirements Could Mean Higher Study Costs
FDA's Pharmaceutical Science and Clinical Pharmacology Advisory Committee agrees with the Office of Generic Drugs that bioequivalence standards should be tighter for generic versions of "critical dose" or "narrow therapeutic index" drugs.